TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04109638

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Endonovo SofPulse
Description: The active device emits PEMF signal whereas the placebo device does not emit a PEMF signal. The active device is on for 15 minutes at a time, every two hours, for 10 days.
Study: NCT06006702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TYRA-300-B01
Description: TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TYRA-300-B01
Description: TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TYRA-300-B01
Description: TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TYRA-300-B01
Description: TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
Study: NCT06193343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Daily Step Promotion
Description: Participants will wear a Fitbit monitor on their non-dominant wrist during a 10 to 14 day run-in screening to capture daily steps reported by the Fitbit but no daily step goals will be sent to the participant. The Fitbit monitor will be worn during all waking hours except water activities, and compliance will be considered as a day with ≥1,000 steps. Next, participants will undergo a 16-week intervention wearing the Fitbit monitor on their wrist and receive a text message each morning with a personalized, adaptive daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day. Goals will not exceed 10,000 daily steps.
Study: NCT05106049

Intervention type: DIAGNOSTIC_TEST
Intervention: serum Adiponectin
Description: serum adiponectin as early marker for renal impairment. Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions.
Study: NCT06532851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise (PRE)
Description: A structured exercise regimen focusing on increasing muscular strength and endurance through progressive resistance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: An exercise program focusing on cardiovascular conditioning using a stationary bike.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A set of general strength and balance exercises that do not target the specific therapeutic goals of the other interventions.
Study: NCT05529277

Intervention type: OTHER
Intervention: Dementia Care Management
Description: Comprehensive assessment of health care needs of person with cognitive impairment and caregiver followed by algorithm-/ and person-based support in health care planning, implementing and monitoring
Study: NCT05362942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax, Decitabine, Azacytidine, Cytarabine
Description: Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days (n=3) or azacytidine (n=8) was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician. Cytarabine was given at a dose of 10 mg/m2 twice daily for 7 days.
Study: NCT05936840

Intervention type: DEVICE
Intervention: Mira Monitor tracking
Description: Using the Mira monitor to track the menstrual cycle

Intervention type: DEVICE
Intervention: Mira Monitor tracking
Description: Using the Mira monitor to track the menstrual cycle

Intervention type: DEVICE
Intervention: Mira Monitor tracking
Description: Using the Mira monitor to track the menstrual cycle
Study: NCT05254990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: Reparixin 600 mg tablets, administered orally at the dose of 1200 mg TID (2 tablets TID) as add-on therapy to standard of care up to 21 days. IMP can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that reparixin is taken with food. However, if the patient is unable to eat, the study drug may still be administered without concomitant food ingestion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally three times a day (TID) as add-on therapy to standard of care up to 21 days.~Placebo can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that placebo is taken with food. However, if the patient is unable to eat, the placebo may still be administered without concomitant food ingestion.
Study: NCT06311773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boomerang Catheter
Description: The study device used for this procedure makes an anastomosis between a tibial vein and a tibial artery to direct blood flow around blocked arteries.
Study: NCT06631638

Intervention type: DEVICE
Group type: OTHER
Intervention: EMPHASYS Cup with VHN
Description: Total Hip Replacement with EMPHASYS Acetabular shell and Non-Invasive Navigation
Study: NCT06631287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: 4mg encapsulated, pre-formed tablet PO once daily for 24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated, pre-formed tablet PO once daily for 24 weeks.
Study: NCT04585477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVENIO ctDNA Surveillance Kit
Description: Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AVENIO ctDNA Surveillance Kit
Description: Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants in the intervention arm will receive Durvalumab (1500 mg IV every 4 weeks for up to 12 months) as monotherapy or 20mg/kg if weight is 30kg or less.
Study: NCT05739279

Intervention type: DIAGNOSTIC_TEST
Intervention: STAR-Sonographic Thigh Adjustment Ratio
Description: With ultrasonography, anterior thigh muscle thickness on the dominant extremity side will be measured at a 50% level between the anterior superior iliac spine and the upper pole of the patella in the supine position. The STAR-sonographic thigh adjustment ratio will be calculated by dividing the anterior thigh muscle thickness (mm) by the body mass index.

Intervention type: DIAGNOSTIC_TEST
Intervention: STAR-Sonographic Thigh Adjustment Ratio
Description: With ultrasonography, anterior thigh muscle thickness on the dominant extremity side will be measured at a 50% level between the anterior superior iliac spine and the upper pole of the patella in the supine position. The STAR-sonographic thigh adjustment ratio will be calculated by dividing the anterior thigh muscle thickness (mm) by the body mass index.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hand Grip Strength
Description: Hand grip strength will be measured with a Jamar dynamometer used in the second grip position, in a sitting position with shoulders adducted and neutrally rotated, elbows flexed to 90°, and forearms/wrists in the neutral position. Three repetitive measurements will be made from the dominant side and the maximum value obtained for analysis will be taken.
Study: NCT04585477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
Description: Participants in the intervention arm (Cohort 1 MRD+) will receive a fixed dose of Durvalumab (1500 mg IV every 4 weeks for up to 12 months), either as monotherapy or in combination with a platinum-based chemotherapy regimen (investigator's choice). Platinum-based chemotherapy options include carboplatin, cisplatin, pemetrexed, paclitaxel, or nab-paclitaxel, administered per standard of care for up to 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
Description: Participants in the intervention arm (Cohort 1 MRD+) will receive a fixed dose of Durvalumab (1500 mg IV every 4 weeks for up to 12 months), either as monotherapy or in combination with a platinum-based chemotherapy regimen (investigator's choice). Platinum-based chemotherapy options include carboplatin, cisplatin, pemetrexed, paclitaxel, or nab-paclitaxel, administered per standard of care for up to 4 cycles.
Study: NCT05739279

Intervention type: DIAGNOSTIC_TEST
Intervention: Hand Grip Strength
Description: Hand grip strength will be measured with a Jamar dynamometer used in the second grip position, in a sitting position with shoulders adducted and neutrally rotated, elbows flexed to 90°, and forearms/wrists in the neutral position. Three repetitive measurements will be made from the dominant side and the maximum value obtained for analysis will be taken.

Intervention type: DIAGNOSTIC_TEST
Intervention: Chair Stand Test
Description: For the 5-repeat stand-up test, patients will be asked to get up from a chair without an armrest and sit (at the start) five times as fast as possible with their arms crossed over their chest.
Study: NCT06430866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 234
Description: Administered by intravenous (IV) injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered by IV injection.
Study: NCT06190223

Intervention type: PROCEDURE
Intervention: Anterior cruciate ligament (ACL) reconstruction with a periost-patellar-tendon-bone (PPTB) autograft and a tibial press-fit technique
Description: A longitudinal incision will be performed starting from the central part of the patella. A ruler will be used to mark a tendon thickness of 10mm from the middle of the patellar tendon. Superiorly, the patellar periosteum will be marked with a length of 30-40mm and a width of 10mm. Inferiorly, the tibial tubercle will be marked in a trapezoidal shape with a length of approximately 35mm, a superior narrow base of 10mm and an inferior wider base of 12mm. After extraction, the superior part of the graft will be prepared with reinforced sutures in a whipstitch pattern, while the bone block will be shaped according to the planned tunnel width. After adequate preparation, the femoral end of the graft will be shuttled in with an adjusted fixation device, while the tibial end will be hammered in with a small mallet, in a press-fit fashion, stopping short of the joint surface, but tensioned appropriately. The femoral adjustable device will then be tensioned to ensure proper graft sitting.
Study: NCT04910724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Deficit
Description: A combination of individualized exercise performed on a cycle ergometer and individualized dietary prescriptions will be used to achieve energy balance or the assigned energy deficits throughout the controlled feeding and testing periods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Deficit
Description: A combination of individualized exercise performed on a cycle ergometer and individualized dietary prescriptions will be used to achieve energy balance or the assigned energy deficits throughout the controlled feeding and testing periods
Study: NCT05739279

Intervention type: DIAGNOSTIC_TEST
Intervention: Chair Stand Test
Description: For the 5-repeat stand-up test, patients will be asked to get up from a chair without an armrest and sit (at the start) five times as fast as possible with their arms crossed over their chest.
Study: NCT04910724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Deficit
Description: A combination of individualized exercise performed on a cycle ergometer and individualized dietary prescriptions will be used to achieve energy balance or the assigned energy deficits throughout the controlled feeding and testing periods
Study: NCT06161584

Intervention type: DRUG
Intervention: Pegcetacoplan
Description: Administered intravitreally (IVT) in eyes with geographic atrophy (GA)
Study: NCT05739279

Intervention type: DIAGNOSTIC_TEST
Intervention: 6 Meter Gait Speed
Description: For walking speed measurements, patients will be asked to stand with both feet touching the starting line and walk at their normal speed on a 6-meter track after the command. The time between the start and end will be measured with a stopwatch and converted to meters/second. Three consecutive measurements will be made for both and average values will be taken for the analyses.

Intervention type: DIAGNOSTIC_TEST
Intervention: 6 Meter Gait Speed
Description: For walking speed measurements, patients will be asked to stand with both feet touching the starting line and walk at their normal speed on a 6-meter track after the command. The time between the start and end will be measured with a stopwatch and converted to meters/second. Three consecutive measurements will be made for both and average values will be taken for the analyses.
Study: NCT05062889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil continuous infusion FOLFOXIRI schedule
Description: 3200 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study: NCT05960578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05062889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil bolus FOLFOX schedule
Description: 400 mg/sqm iv bolus, day 1. To be repeated every two weeks for a maximum of 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil bolus FOLFOX schedule
Description: 400 mg/sqm iv bolus, day 1. To be repeated every two weeks for a maximum of 12 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil continuous infusion FOLFOX schedule
Description: 2400 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil continuous infusion FOLFOX schedule
Description: 2400 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin FOLFOX and FOLFOXIRI schedule
Description: 85 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study: NCT05960578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET
Study: NCT06304181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol and Mannitol Injection
Description: Paracetamol and Mannitol Injection 500mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parecoxib
Description: 40mg of parecoxib
Study: NCT06292416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Mirror therapy with sensory motor training.
Description: Block design, finding shapes in pictures, puzzles, matching geometric shapes and letters, numbers, and classification.~Pointing to the body parts, life-size drawing, turning left and right side and awareness of the body parts through touch.~feeling various textures, touching boards, and feeling shapes. Ocular-pursuit training, moving ball and pegboard activities During the sessions, subjects were asked to try and do the same movement with the paretic hand simultaneously The patients will be asked to repeat each movement 20 times per set for three sets, with a 2-minute break between sets.~Session will last for 45 mins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Mirror Therapy with motor training
Description: the participant is asked to perform a forearm movement sting on the paretic side while the subjects look into the mirror, watching the image of their non-involved hand and thus seeing the reflection of the hand movement projected over the involved hand. During the sessions subjects were asked to try and do the same movement with the paretic hand simultaneously. movement was repeated 20 times per set for three sets, with a 2-minute break between sets

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental: Motor Training
Description: 1. Holding object with two hands, clapping, banging objects together.~2. Stabilize objects with one hand while the other is manipulating (holding paper while coloring, holding a container while putting objects in)~3. manipulate objects with both hands simultaneously (stringing beads, tying a knot),~4. ask child to padlock in which a key can be put into, markers with caps to put on, a box with a lid and objects to put inside the box~5. hold a cup with one hand while putting object in with other hand~6. Buttoning with both hands, tying a bow. doing craft project, fitting blocks together
Study: NCT05062889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin FOLFOX and FOLFOXIRI schedule
Description: 85 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study: NCT05343494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The intervention has been modified from a subset of sessions from the National DPP Prevent T2 Curriculum (an adapted DPP for community settings that improves cardiometabolic outcomes and is implemented nationwide).~The intervention will consist of 8 weekly sessions. The first session will be one-on-one and subsequent sessions will be in small groups. Sessions 1, 2, and 6 will be in-person and other sessions will be held by Zoom.
Study: NCT05062889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin FOLFOX and FOLFOXIRI schedule
Description: 85 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin CAPOX schedule
Description: 130 mg/sqm iv over 2 hours, day 1. To be repeated every three weeks for a maximum of 8 cycles.
Study: NCT05348356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: nirogacestat oral tablet
Study: NCT05062889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin CAPOX schedule
Description: 130 mg/sqm iv over 2 hours, day 1. To be repeated every three weeks for a maximum of 8 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Leucovorin
Description: 200 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study: NCT04931745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: VR headset will be used 5-10 minutes prior to and during port access

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tables distraction
Description: Tablet distraction will be used 5-10 minutes prior to and during port access

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No or non-technologic distraction
Description: This approach will be used 5-10 minutes prior to and during port access
Study: NCT05605587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide 20 mg
Description: once daily for 6 months
Study: NCT06386601

Intervention type: OTHER
Group type: OTHER
Intervention: Ergonomics Knowledge
Description: Participants will participate in a lecture/module on surgical ergonomics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomics Knowledge
Description: Participants will participate in a lecture/module on surgical ergonomics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomics Feedback/Guided Practice
Description: Participants will practice minimally invasive surgical skills while receiving feedback on ergonomic positioning/practice
Study: NCT05358262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo
Description: Fisher \& Paykel's AIRVO 2 is a humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases to spontaneously breathing patients through a variety of interfaces including nasal cannula. Flow can be delivered from 2 to 60 LPM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The standard of care for mucositis at the Cross Cancer institute involves supportive therapies including oral hydration (water or wet sponges) or medicated mouthwashes.
Study: NCT05634720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA Chemotherapy
Description: Patients will receive the interventional treatment, which is neoadjuvant HA chemotherapy (FUDR/oxaliplatin delivered via the Hepatic Artery).
Study: NCT05312515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm Application to Feet
Description: Warm Application to Feet after Cesarean Section
Study: NCT05864612

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening Questionnaires
Description: Standard care screening questionnaires on anxiety and depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening Questionnaires
Description: Standard care screening questionnaires on anxiety and depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening Questionnaires
Description: Standard care screening questionnaires on anxiety and depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening Questionnaires
Description: Standard care screening questionnaires on anxiety and depression
Study: NCT05698355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Treatment
Description: Telerehabilitation includes self-massages for pelvic floor muscle, sex education, breathing, myofascial releasing with wand, and pelvic floor relaxing exercises.
Study: NCT05682937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFOV-sigh
Description: HFOV-sigh setting both SLE6000 and Drager Babylog VN500: setting (Hz, MAP, delta pressure) same as HFOV, set sigh RR 3 breath/min, Sigh Ti = 1 sec, Sigh PIP = (MAP+5, maximum 30) cm H2O, Slope sigh 0.5.
Study: NCT04323774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AYA-RISE Adolescents and Young Adults Risk Information and Screening Education
Description: A chatbot is a computer program that can chat with humans. The text the chatbot uses to talk with humans was created by real people, but the chatbot itself is not a real person. A company called Clear Genetics developed the original chatbot and patient portal, and this study team customized it for this research study.